Comparative effects of levosimendan and dobutamine infusion on p wave dispersion in patients with acute decompensated heart failure;Akut dekompanze kalp yetmezlikli hastalarda levosimendan ve dopamin infüzyonunun p dalga dispersiyonu üzerine olan karşi{dotles}laşti{dotles}rmali{dotles} etkileri

Turkish Journal of Medical Sciences

Volumn 40, Issue 5, 2010, Pages 761-770

  Iyisoy, Atila ^a   Çelik, Turgay ^a   Çelik, Murat ^a   Buǧan, Bariş ^a   Yaman, Halil ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

Acute decompensated heart failure; Dobutamine; Levosimendan; P wave dispersion

Indexed keywords

ATRIAL FIBRILLATION; BEFORE AND AFTER; CLINICAL DATA; COMPUTER SCREENS; DOBUTAMINE; HEART FAILURE; HEMODYNAMIC IMPROVEMENT; HIGH RESOLUTION; LEVOSIMENDAN; MEAN AGES; P WAVES; P-WAVE DISPERSION; WAVE DISPERSION;

DISPERSIONS; HEART; MEDICAL COMPUTING; SEISMIC WAVES;

DISPERSION (WAVES);

DOBUTAMINE; LEVOSIMENDAN;

ACUTE DECOMPENSATED HEART FAILURE; ADULT; AGED; ARTICLE; CARDIOLOGIST; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ANALYSIS; CONGESTIVE CARDIOMYOPATHY; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIASTOLIC BLOOD PRESSURE; ECHOCARDIOGRAPHY; FEMALE; HEART ATRIUM FIBRILLATION; HEART ELECTROPHYSIOLOGY; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HUMAN; LOADING DRUG DOSE; MALE; ONSET AGE; P WAVE; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; THERAPY EFFECT;

EID: 78049316865     PISSN: 13000144     EISSN: None     Source Type: Journal    
DOI: 10.3906/sag-1004-759     Document Type: Article

References (27)

1. Felker GM, O'Connor CM. Inotropic therapy for heart failure: an evidence-based approach. Am Heart J 2001; 142: 393-401.
2. Cuffe MS, Califf RM, Adams KF Jr, Benza R, Bourge R, Colucci WS et al. Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Investigators. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002; 287: 1541-1547.
3. Bayram M, De Luca L, Massie MB, Gheorghiade M. Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes. Am J Cardiol 2005; 96: 47G-58G.
4. Haikala H, Kaivola J, Nissinen E, Wall P, Levijoki J, Lindén IB. Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol 1995; 27: 1859-1866.
5. Pollesello P, Ovaska M, Kaivola J, Tilgmann C, Lundström K, Kalkkinen N et al. Binding of a new Ca2+ sensitizer, levosimendan, to recombinant human cardiac troponin C. A molecular modelling, fluorescence probe, and proton nuclear magnetic resonance study. J Biol Chem 1994; 269: 28584-28590.
6. Kass DA, Solaro RJ. Mechanisms and use of calcium-sensitizing agents in the failing heart. Circulation 2006; 113: 305-315.
7. Parissis JT, Filippatos G, Farmakis D, Adamopoulos S, Paraskevaidis I, Kremastinos D. Levosimendan for the treatment of acute heart failure syndromes. Expert Opin Pharmacother 2005; 6: 2741-2751.
8. Slawsky MT, Colucci WS, Gottlieb SS, Greenberg BH, Haeusslein E, Hare J et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. Circulation 2000; 102: 2222-2227.
9. Nieminen MS, Akkila J, Hasenfuss G, Kleber FX, Lehtonen LA, Mitrovic V et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 2000; 36: 1903-1912.
10. Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K et al. Steering Committee and Investigators of the Levosimendan Infusion versus Dobutamine (LIDO) Study. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002; 360: 196-202.
11. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991; 325: 1468-1475.
12. Nony P, Boissel JP, Lievre M, Leizorovicz A, Haugh MC, Fareh S et al. Evaluation of the effect of phosphodiesterase inhibitors on mortality in chronic heart failure patients. A metaanalysis. Eur J Clin Pharmacol 1994; 46: 191-196.
13. Singh BN, Lilleberg J, Sandell E-P, Ylönen V, Lehtonen L, Toivonen L. Effects of levosimendan on cardiac arrhythmias: electrophysiologic and ambulatory electrocardiographic findings in Phase II and III clinical studies in cardiac failure. Am J Cardiol 1999; 24 Suppl I: 16(I)-20(I).
14. Lilleberg J, Ylönen V, Lehtonen L, Toivonen L. The calcium sensitizer levosimendan and cardiac arrhythmias: an analysis of the safety database of heart failure treatment studies. Scand Cardiovasc J 2004; 38: 80-84.
15. Dilaveris P, Batchvarov V, Gialafos J, Malik M. Comparison of different methods for manual P-wave duration measurement in 12-lead electrocardiograms. Pacing Clin Electrophysiol 1999; 22: 1532-1538.
16. Edes I, Kiss E, Kitada Y, Powers FM, Papp JG, Kranias EG et al. Effects of Levosimendan, a cardiotonic agent targeted to troponin C, on cardiac function and on phosphorylation and Ca2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart. Circ Res 1995; 77: 107-113.
17. Sorsa T, Pollesello P, Solaro RJ. The contractile apparatus as a target for drugs against heart failure: interaction of levosimendan, a calcium sensitiser, with cardiac troponin C. Mol Cell Biochem 2004; 266: 87-107.
18. Haikala H. Non-clinical studies on arrythmogenity of levosimendan. Research Report: Orion Pharma; 2003 November 11 Report No: NDO090017.
19. Moiseyev VS, Põder P, Andrejevs N, Ruda MY, Golikov AP, Lazebnik LB et al. RUSSLAN Study Investigators. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 2002; 23: 1422-1432.
20. Binkley PF, Nunziata E, Hatton PS, Leier CV. The positive inotropic agent levosimendan mediates increased cardiac output without progression of sympathovagal imbalance in patients with heart failure. Circulation 2000; 102 (Suppl II): 720-721.
21. Toivonen L, Viitasalo M, Sundberg S, Akkila J, Lehtonen L. Electrophysiologic effects of a calcium sensitizer inotrope levosimendan administered intravenously in patients with normal cardiac function. J Cardiovasc Pharmacol 2000; 35: 664-669.
22. Packer M. REVIVE II: Multicenter placebo-controlled trial of levosimendan on clinical status in acutely decompensated heart failure. Program and abstracts from the American Heart Association Scientific Sessions 2005; November 13-16, 2005; Dallas, Texas. Late Breaking Clinical Trials II.
23. Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ et al. SURVIVE Investigators. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 2007; 297: 1883-1891.
24. Dilaveris PE, Gialafos JE. P-wave dispersion: A novel predictor of paroxysmal atrial fibrillation. Ann Noninvasive Electrocardiol 2001; 6: 159-165.
25. Parissis JT, Panou F, Farmakis D, Adamopoulos S, Filippatos G, Paraskevaidis I et al. Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure. Am J Cardiol 2005; 96: 423-426.
26. Janssen PM, Datz N, Zeitz O, Hasenfuss G. Levosimendan improves diastolic and systolic function in failing human myocardium. Eur J Pharmacol 2000; 404: 191-199.
27. Tachibana H, Cheng HJ, Ukai T, Igawa A, Zhang ZS, Little WC et al. Levosimendan improves LV systolic and diastolic performance at rest and during exercise after heart failure. AmJ Physiol Heart Circ Physiol 2005; 288: H914-H922.